VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 43 filers reported holding VERONA PHARMA PLC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $6,976 | -89.5% | 428 | -86.4% | 0.00% | -100.0% |
Q2 2023 | $66,337 | +72797.8% | 3,138 | -30.8% | 0.00% | -33.3% |
Q1 2023 | $91 | +378.9% | 4,534 | +520.2% | 0.00% | +200.0% |
Q4 2022 | $19 | -99.7% | 731 | +32.2% | 0.00% | – |
Q3 2022 | $6,000 | -25.0% | 553 | -74.0% | 0.00% | – |
Q2 2022 | $8,000 | +60.0% | 2,126 | +106.2% | 0.00% | – |
Q1 2022 | $5,000 | +150.0% | 1,031 | +209.6% | 0.00% | – |
Q4 2021 | $2,000 | -80.0% | 333 | -81.3% | 0.00% | – |
Q3 2021 | $10,000 | +11.1% | 1,777 | +30.2% | 0.00% | – |
Q2 2021 | $9,000 | +800.0% | 1,365 | +582.5% | 0.00% | – |
Q2 2020 | $1,000 | 0.0% | 200 | -23.7% | 0.00% | – |
Q2 2019 | $1,000 | -50.0% | 262 | -28.4% | 0.00% | – |
Q1 2019 | $2,000 | -50.0% | 366 | -17.2% | 0.00% | – |
Q4 2018 | $4,000 | +33.3% | 442 | +73.3% | 0.00% | – |
Q3 2018 | $3,000 | 0.0% | 255 | 0.0% | 0.00% | – |
Q2 2018 | $3,000 | -66.7% | 255 | -45.7% | 0.00% | -100.0% |
Q1 2018 | $9,000 | +200.0% | 470 | +136.2% | 0.00% | – |
Q3 2017 | $3,000 | – | 199 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,332,485 | $34,817,833 | 22.99% |
Abingworth LLP | 2,457,500 | $64,214,475 | 20.92% |
Fairmount Funds Management LLC | 2,875,526 | $75,137,494 | 11.92% |
Octagon Capital Advisors LP | 2,468,000 | $64,488,840 | 10.04% |
NEA Management Company, LLC | 5,584,753 | $145,929,596 | 8.20% |
Knoll Capital Management, LLC | 95,391 | $2,492,567 | 5.62% |
Frazier Life Sciences Management, L.P. | 2,815,720 | $73,574,764 | 4.57% |
Resolute Capital Asset Partners LLC | 185,992 | $4,860 | 4.34% |
Caligan Partners LP | 183,064 | $4,783,462 | 3.98% |
Samsara BioCapital, LLC | 695,001 | $18,160,376 | 3.91% |